WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017066697) TREATMENTS AND DIAGNOSTICS FOR CANCERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/066697 International Application No.: PCT/US2016/057210
Publication Date: 20.04.2017 International Filing Date: 14.10.2016
IPC:
A61K 31/4155 (2006.01) ,A61K 31/4196 (2006.01) ,A61K 31/4375 (2006.01)
Applicants: DOU, Qingping[US/US]; US
YANG, Huanjie[CN/US]; US
HEATH, Elisabeth I.[US/US]; US
Inventors: DOU, Qingping; US
YANG, Huanjie; US
HEATH, Elisabeth I.; US
Agent: WINGER, C. Rachal; US
Priority Data:
62/241,57414.10.2015US
62/259,42624.11.2015US
Title (EN) TREATMENTS AND DIAGNOSTICS FOR CANCERS
(FR) TRAITEMENTS ET DIAGNOSTICS DE CANCERS
Abstract: front page image
(EN) Treatments and diagnostics for treatment efficacy against solid and liquid cancers are described. The treatments utilize a combination therapy of Galeterone and a proteasome inhibitor. The diagnostics can measure androgen receptor (AR) cleavage products including AR-variant 7 (AR-V7) cleavage products, Poly (ADP-ribose) polymerase (PARP) cleavage products, and/or Spectrin α2 cleavage products or inhibition of DUB activities from a blood sample to monitor treatment efficacy for castration-resistant prostate cancer (CRPC) or multiple myeloma (MM).
(FR) L'invention concerne des traitements et des diagnostics assurant l'efficacité des traitements contre des cancers solides et liquides. Les traitements font appel à une polythérapie utilisant la galétérone et un inhibiteur du protéasome. Ce diagnostic permet de mesurer des produits de clivage du récepteur des androgènes (AR) tels que des produits de clivage du variant 7-AR (AR-V7), des produits de clivage de la poly(ADP-ribose) polymérase (PARP), et/ou des produits de clivage de la spectrine alpha 2 ou l'inhibition des activités des enzymes de désubiquitination (DUB) dans un échantillon de sang afin de surveiller l'efficacité du traitement du cancer de la prostate hormono-résistant(CRPC) ou du myélome multiple (MM).
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)